Supreme Court ruling supports generic drug makers

April 18, 2012

The US Supreme Court ruled Tuesday that generic drug makers can challenge big-name pharmaceutical firms in court to stop them from broadening the scope of their patent descriptions.

The measure overturns a 2010 appeals court ruling and confirms an earlier decision by a federal judge that ordered the US subsidiary of Danish laboratory Novo Nordisk to narrow the description of its patent on repaglinide, an anti-diabetes drug sold under the name Prandin.

Caraco Pharmaceutical Laboratories, the US subsidiary of the Indian firm Sun Pharmaceutical Industries, is seeking to produce a of Prandin.

However Novo Nordisk amended the wording of his patent to extend it, and block the Caraco's request to the (FDA) to produce a generic version of the drug.

The FDA cannot approve the sale of a drug that breaks laws.

In a unanimous decision by the nine Supreme Court justices, Justice Elena Kagan wrote that "a generic company can employ the counterclaim to challenge a brand's overbrand use code."

"We accordingly hold that Caraco may bring a counterclaim seeking to 'correct' Novo's use code," the ruling read.

"While we are disappointed with the decision," said James Shehan, a senior official with Novo Nordisk Inc, USA, "it appears the Supreme Court has held only that Caraco may challenge the use code narrative for Novo Nordisk's patented method of treating diabetes with repaglinide in combination with metformin.

"Novo Nordisk's use code narrative is, and has always been, correct, and we are confident that further proceedings will show Caraco's challenge to the use code narrative is meritless," Shehan said.

In 2011, US sales of Novo Nordisk drugs Prandin and PrandiMet totaled $175.96 million (about one billion Danish kroner), according to the firm.

Explore further: FDA notes heart events, tumors with Novo drug

Related Stories

FDA notes heart events, tumors with Novo drug

March 31, 2009

(AP) -- Federal health officials say a potential blockbuster diabetes drug from Novo Nordisk appears to work. But they say questions remain about its effect on the heart and other organs.

Novo Nordisk says to market improved insulin in 2013

December 23, 2010

Danish pharmaceutical company Novo Nordisk said Thursday it planned to put a new insulin product on the market by 2013 after tests showed advantages to the widely sold diabetes drug Lantus.

Novo Nordisk pays $26.7 million to settle claims

June 11, 2011

Danish drug company Novo Nordisk has agreed to pay $25 million to settle allegations that it promoted the misuse of blood clotting drug NovoSeven, the US Justice Department announced Friday.

Paula Deen pledges money to diabetes association

January 19, 2012

(AP) -- Celebrity chef Paula Deen on Wednesday pledged a portion of her earnings from a lucrative endorsement deal with a diabetes drugmaker to the nonprofit American Diabetes Association.

S. Korea to approve Viagra generics

March 14, 2012

Three South Korean pharmaceutical firms will soon be allowed to produce generic versions of the anti-impotence drug Viagra despite a row over patents, officials said Wednesday.

Recommended for you

Treatment options for opioid addiction are expanding

August 10, 2016

In the past two decades, the devastation associated with opioid addiction has escaped the relative confines of the inner city and extended to suburban and rural America. Due in large part to the proliferation of prescription ...

Can exercise be replaced with a pill?

October 2, 2015

Everyone knows that exercise improves health, and ongoing research continues to uncover increasingly detailed information on its benefits for metabolism, circulation, and improved functioning of organs such as the heart, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.